That Discount at the Pharmacy Counter May Pack Hidden Costs
The new TrumpRx program relies partly on connecting consumers with discount coupons offered by drugmakers. For insured patients, though, using a coupon can prove dicey.
Drugs
1 - 20 of 1,292 Results
-
-
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
By Elisabeth Rosenthal and Arthur Allen -
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
It may soon get easier for millions of people with Medicare to get discounted GLP-1 drugs for weight loss.
The Supreme Court Case That Could Slow Generic Drugs
Season 15, Episode 6In “Hikma v. Amarin,” the Supreme Court’s decision could affect how quickly generic versions of brand-name medicines come to market.
The Accidental Architect of America’s Drug Patent Problem
Season 15, Episode 5An Arm and a Leg launches its “101” series with the story of Alfred Engelberg, a lawyer who’s been crusading to improve access to generic drugs by fixing loopholes in a law he helped draft more than 40 years ago.
-
Journalists Capsulize Weight Loss News and ACA Premium Pressures
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
-
Readers Sound Off on Wage Garnishment, Work Requirements, and More
KFF Health News gives readers a chance to comment on a recent batch of stories.
-
Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
So you’ve decided to go on a GLP-1 to lose weight. These medicines might seem like an easy way to drop unwanted pounds, but you’ll likely need to do a few other things to be successful long-term.
-
Maker of Device To Treat Addiction Withdrawal Seeks Counties’ Opioid Settlement Cash
Some researchers and recovery advocates see the NET device as the latest in a series of products pitched as the solution to the addiction crisis that have been overhyped to capitalize on money from the opioid settlements.
RFK Jr.’s Very Bad Week
Episode 437HHS Secretary Robert F. Kennedy Jr. had another tough week. In addition to Kennedy having rotator cuff surgery, the nomination of his ally to become surgeon general is teetering, the controversial head of the FDA's vaccine center is resigning next month, and a new survey shows Americans trust government health officials less than they do former Biden official Anthony Fauci. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, and Shefali Luthra of The 19th join KFF Health News’ Julie Rovner to discuss these stories and more.
-
He Needs an Expensive Drug. A Copay Card Helped — Until It Didn’t.
Diagnosed with an autoimmune disorder, a California man was prescribed a drug that costs thousands of dollars a month. He said he was reassured that the drugmaker’s copay card would cover his share, but after two months, the card was empty.
-
As More Americans Embrace Anxiety Treatment, MAHA Derides Medications
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, claiming they’re harmful. Doctors and researchers say the MAHA movement is misrepresenting drugs that have been proved to safely treat chronic anxiety and point to broader social changes to explain their increased use.
-
Should Drug Companies Be Advertising to Consumers?
Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans.
By Paula Span New Flu Vax? FDA Says No Thanks
Episode 433It’s been a busy week at the FDA, with a political appointee overruling agency scientists to reject an application for a new flu vaccine. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Jackie Fortiér of KFF Health News, Lizzy Lawrence of Stat, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more.
-
Effective but Underprescribed: HIV Prevention Meds Aren’t Reaching Enough People
PrEP has been available for more than a decade, but billing mistakes, lack of awareness, and lingering stigma keep many people from getting the lifesaving HIV prevention medication.
By Zach Dyer -
It’s 2026 and You’re Uninsured. Now What?
Many Americans are expected to lose ACA or Medicaid coverage in coming months and years as a result of the One Big Beautiful Bill Act and the expiration of enhanced pandemic-era subsidies that helped people afford Obamacare plans. Doctors and researchers say there are still ways to find affordable care.
-
This Teen Never Got His Day in Vaccine Court. His Former Lawyer Now Advises RFK on Its Overhaul.
The federal government’s Vaccine Injury Compensation Program was supposed to help patients with their medical bills while protecting vaccine supply. But allies of Health and Human Services Secretary Robert F. Kennedy Jr. are routinely transferring cases from that program to launch lawsuits against drugmakers.
-
Why Medication Abortion Is the Top Target for Anti-Abortion Groups in 2026
With abortions still on the rise nationwide despite widespread bans, curtailing the use of pregnancy-terminating medication is a top priority for abortion opponents — and they’re frustrated that the Trump administration isn’t doing more to limit its use.
By Julie Rovner Health Spending Is Moving in Congress
Episode 430Lawmakers appear on the brink of passing a spending bill for the Department of Health and Human Services and a bipartisan health policy bill delayed for over a year. But the outlook is bleaker for the health care outline released by President Trump last week. Sandhya Raman of CQ Roll Call, Sheryl Gay Stolberg of The New York Times, and Paige Winfield Cunningham of The Washington Post join KFF Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews oncologist and bioethicist Ezekiel Emanuel to discuss his new book, “Eat Your Ice Cream.”
-
Medicaid Tries New Approach With Sickle Cell: Companies Get Paid Only if Costly Gene Therapies Work
The government is using sickle cell treatments to test a new strategy: paying only if the therapies benefit patients. With more expensive treatments on the horizon, the program — created by the Biden administration and continued under President Trump — could help Medicaid save money and treat more patients.